清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 3134: Preclinical anti-glioblastoma pharmacology of HX301, a novel CSF-1R inhibitor

胶质母细胞瘤 医学 药理学 癌症研究
作者
Tao Yang,Hang Ke,Jessie Wang,Shunbin Xiong,Lei Zhang,Faming Zhang,Henry Qixiang Li
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 3134-3134
标识
DOI:10.1158/1538-7445.am2025-3134
摘要

Abstract Background. GBM is the most malignant and frequently occurring glioma (>60% of all brain tumors in adults) with poor prognosis (12-18 months survival time after diagnosis and 5-year survival of ∼5%) and an unmet medical need. Glioma-associated macrophages/microglia (GAMs) are the prominent and suppressive immune cells in the tumor microenvironment (TME), promoting the growth, migration, invasion and stemness of tumor cell . GAMs also secret VEGF to promote angiogenesis and TGF-β to suppress immunity. Notably, the numbers of surrounding GAM inversely correlate with the prognosis. CSF1R, together with its two ligands, CSF1 (M-CSF) and IL-34, governs the proliferation, polarization, differentiation and functions of the myeloid lineage cells, including macrophage/microglia in GBM. Blocking CSF1/CSF1R signaling inhibits microglia/macrophage proliferation and delayed tumor growth by depleting GAMs and diminishing their tumor-promoting activities. HX301 (Narazaciclib or ON123300) is a clinical-stage tyrosine kinase inhibitor (TKI, NCT#05731934) with great potency against CSF1R (IC50 0.285nM) and has demonstrated significant inhibition on macrophage proliferation in vitro/in vivo as well as capability of penetrating brain-blood-barrier (BBB). We hypothesized it has anti-GBM activity. Methods. A single dose of HX301 (30 mg/kg) was orally administrated in NOD/Scid mice, followed by plasma and brain tissues collection at designated timepoints and the drug concentration determination by LC-MS. Anti-GBM pharmacology of the drug was assessed in the following preclinical models: 1) subcutaneous U87-MG xenograft; 2) orthotopic GL261-Red-Fluc syngeneic mouse GBM model; and 3) orthotopic BN2289-Luc PDX model, respectively. HX301, Temozolomide (TMZ), or their combination were oral-administrated daily. tumor-focused-irradiation was also performed using a X-RAD320 (Precision X-Ray, 15-Gy two days after randomization). Results. The mouse PK study showed that HX301 efficiently penetrate BBB resulting in adequate exposure in brain for activity. In the three GBM pharmacology modeling, HX301 alone significantly inhibited the tumor growth, of which the anti-tumor activity seen in the orthotopic GL261-Red-Fluc and BN2289-Luc models also confirmed HX301 penetration BBB to exert its anti-tumor effects, possibly acting on the macrophages or microglia in the TME. Moreover, although HX301 and radiation combo failed to show any synergistic effects in orthotopic GL261-Red-Fluc model, HX301 in combination with TMZ exhibited significantly stronger anti-tumor activities over either HX301 alone or TMZ alone in the subcutaneous U87-MG model, suggesting a synergistic effect between the two. Conclusions. HX301 demonstrated great ability to penetrate BBB and robust anti-tumor efficacy, as well as enhanced activity when combined with TMZ, in GBM models, which warrants a further clinical investigation. Citation Format: Tao Yang, Hang Ke, Jessie Wang, Steven Xiong, Lei Zhang, Faming Zhang, Henry Qixiang Li. Preclinical anti-glioblastoma pharmacology of HX301, a novel CSF-1R inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3134.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
车厘子完成签到,获得积分10
30秒前
含蓄的新柔完成签到,获得积分10
36秒前
虫子完成签到,获得积分10
39秒前
spinon完成签到,获得积分10
54秒前
乐乐的应助被虚幻乌冬面采纳,获得10
58秒前
1分钟前
香蕉觅云的应助被GIA采纳,获得10
1分钟前
披着羊皮的狼完成签到 ,获得积分0
1分钟前
沉默怡完成签到,获得积分10
1分钟前
岳鑫完成签到,获得积分10
2分钟前
2分钟前
科研通AI6.3的应助被紫熊采纳,获得10
2分钟前
2分钟前
虚幻乌冬面完成签到,获得积分10
2分钟前
2分钟前
故意的绿真完成签到,获得积分10
2分钟前
MassTestA1的应助被科研通管家采纳,获得20
2分钟前
系统昵称完成签到,获得积分10
2分钟前
Wayne完成签到 ,获得积分10
2分钟前
整齐念薇完成签到,获得积分10
3分钟前
Imran完成签到,获得积分10
3分钟前
风趣馒头完成签到,获得积分10
3分钟前
wuxu完成签到,获得积分10
3分钟前
zjy完成签到,获得积分10
3分钟前
zilv完成签到,获得积分10
3分钟前
3分钟前
紫熊发布了新的文献求助10
3分钟前
矮小的语海完成签到,获得积分10
4分钟前
如歌完成签到,获得积分10
4分钟前
如意嫣完成签到,获得积分10
4分钟前
4分钟前
雪山飞龙完成签到,获得积分10
4分钟前
5分钟前
晚晚的应助被紫熊采纳,获得10
5分钟前
OK的应助被xfy采纳,获得200
5分钟前
优雅的傲柏完成签到,获得积分10
5分钟前
紫熊完成签到,获得积分10
5分钟前
铭坤完成签到 ,获得积分10
5分钟前
linllll完成签到,获得积分10
5分钟前
ding的应助被小文同学采纳,获得20
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195212
求助须知:如何正确求助?哪些是违规求助? 9580926
关于积分的说明 21873010
捐赠科研通 7795208
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484694